# Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients

“Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients” (2019), by Jeffrey J. Popma et al. Medicine research paper. Original abstract below, unchanged. No free PDF was found.

- Authors: Jeffrey J. Popma, G. Michael Deeb, Steven Joseph Yakubov, Mubashir A. Mumtaz, Hemal Gada, Daniel P O’Hair, TANVIR K. BAJWA, John C. Heiser, William M. Merhi, Neal S. Kleiman et al.
- Published: March 16, 2019
- Field: Medicine
- DOI: https://doi.org/10.1056/nejmoa1816885
- Source: https://doi.org/10.1056/nejmoa1816885

## Abstract

BACKGROUND: Transcatheter aortic-valve replacement (TAVR) is an alternative to surgery in patients with severe aortic stenosis who are at increased risk for death from surgery; less is known about TAVR in low-risk patients. METHODS: We performed a randomized noninferiority trial in which TAVR with a self-expanding supraannular bioprosthesis was compared with surgical aortic-valve replacement in patients who had severe aortic stenosis and were at low surgical risk. When 850 patients had reached 12-month follow-up, we analyzed data regarding the primary end point, a composite of death or disabling stroke at 24 months, using Bayesian methods. RESULTS: ). CONCLUSIONS: In patients with severe aortic stenosis who were at low surgical risk, TAVR with a self-expanding supraannular bioprosthesis was noninferior to surgery with respect to the composite end point of death or disabling stroke at 24 months. (Funded by Medtronic; ClinicalTrials.gov number, NCT02701283.).

Canonical page: https://nerdi.pages.dev/paper/W2922215374
Read three real papers a day in Nerdi (iPhone): https://apps.apple.com/app/apple-store/id6813826387?pt=128757794&ct=web-paper&mt=8